Exelixis Inc., of South San Francisco, said renal cell carcinoma drug Cabometyx (cabozantinib) generated net product sales of $90.4 million and $324 million for the fourth quarter and full year, respectively. Cometriq (cabozantinib), approved for progressive, metastatic medullary thyroid cancer, posted sales of $5.3 million and $25 million for the quarter and year, respectively.